Recurrence free interval. May 18, 2021 · Modeling the limitations of IDFS.
Recurrence free interval. Are there differences between progression-free survival, relapse-free survival, and recurrence-free survival? I'm reading on the medical reviews for TNBC and I'm a little bit confused with these Dec 13, 2024 · ctDNA was most frequently detected within 6 months post-treatment in patients with TNBC, aligning with the early recurrence pattern characteristic of the disease. Jun 4, 2025 · The primary end point was the interval of freedom from invasive breast cancer recurrence or death from breast cancer (invasive breast cancer recurrence–free interval). Treatment-free interval is a strong prognostic indicator of overall survival. This retrospective cohort study used data from the Surveillance, Epidemiology, and End Results (SEER) registries to examine associations between distant recurrence-free interval (DRFI) and risk of BC-specific mortality following distant relapse. A number of factors have been shown to be associated with recurrence-free survival and are commonly used to guide decisions regarding treatment (1) including clinical variables such as the patient’s age, pathological markers such as estrogen receptor status, and more recently, genomic markers such as Oncotype DX recurrence score (2). Final analysis was planned after 172 events or 10 years post-study initiation. Conclusions and clinical importance: Tigilanol tiglate provided a durable long-term local response for the treatment of MCT in dogs. There are clinically significant predictors of recurrence and treatment-free interval in UCS, including tumor size and the additional of adjuvant radiation. Breast cancer–free interval includes these events plus either contralateral or ipsilateral breast DCIS. Jun 5, 2025 · The primary endpoint was invasive breast cancer recurrence-free interval (IBCRFI). May 20, 2007 · Recurrence-free interval signifies time from random assignment or registration until invasive recurrence in the ipsilateral breast or locoregionally, at a distant site, or death from breast cancer. Apr 17, 2024 · Recurrence-free survival is a critical outcome in cancer research and clinical practice, as it provides valuable information about the long-term effectiveness of treatments in preventing the return of cancer. Jan 30, 2014 · These two events were therefore not included in any end point except ‘breast cancer-free interval’ for invasive contralateral breast cancer and DFS (iDFS) for ‘second primary invasive cancer (non-breast cancer)’. At the time-driven analysis, 109 IBCRFI events (63% of the planned 172) were confirmed. May 26, 2019 · NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant The following ICEs were considered as potential surrogate endpoints of OS: disease-free survival (DFS), distant disease-free survival (DDFS), distant relapse-free survival (DRFS), recurrence-free survival (RFS), recurrence-free interval (RFI), distant recurrence-free interval (DRFI), breast cancer-free interval (BCFI), and invasive breast . Of evaluable patients, 57 (89%) remained tumor free at the treatment site and 7 (11%) had developed recurrence. Some recommendations were made during the face-to-face meeting. Common wisdom suggests that for time-to-event end points, such as IDFS or recurrence-free interval (RFI), more events means more power. All recurrences occurred within the first 6 months, predominantly (5/7, 71%) within the first 12 weeks. May 18, 2021 · Modeling the limitations of IDFS. 1y di3gtdqe odxpplp 3dile zbgi kmb8 lbk 2d 3jkvvefn gnu